U.S. commits to aggressive global TB elimination with mandatory transparency
S. 4751 — End Tuberculosis Now Act of 2026 · Filed by Todd Young (R-IN) · 1 cosponsor · Introduced Jun 11, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the U.S. government to significantly expand foreign aid for tuberculosis prevention, diagnosis, and treatment globally through 2032, with specific goals to reduce TB incidence by 80% and mortality by 90% by 2030. It requires annual reporting on program outcomes, coordinates efforts across federal agencies and international partners, and emphasizes reaching high-risk populations, drug-resistant TB cases, and integrating TB care into broader health systems.
Why we flagged it
The bill is a straightforward authorization for expanded U.S. foreign assistance targeting a specific infectious disease with clear public-health and pandemic-preparedness rationales. It is not a tax measure, appropriation, or regulatory change—it is a policy directive to the executive branch.
What the text implies
- Establishes TB control programs as explicit platforms for pandemic preparedness, potentially expanding U.S. health surveillance and data-sharing infrastructure in partner countries.
- Mandatory annual reporting through 2032 creates sustained congressional oversight and may influence future appropriations decisions on global health spending.
- Emphasis on private-sector engagement and research partnerships may accelerate development of new TB diagnostics and treatments, with potential commercial applications.
- Integration of TB care into primary health systems in partner countries could strengthen overall health infrastructure but may also create dependency on U.S. funding and technical standards.
Who it affects
Ordinary Americans benefit from reduced global TB transmission (a respiratory disease that can spread internationally), strengthened pandemic preparedness infrastructure, and alignment with U.S. public health security interests. The bill prioritizes cost-effective diagnosis and treatment, transparency through mandatory reporting, and coordination to avoid duplication—all public goods. No direct costs to U.S. taxpayers are specified in the text; the bill authorizes spending but does not appropria
Who stands to gain
- pharmaceutical companies (TB drug and vaccine developers)
- diagnostic equipment manufacturers
- global health NGOs and implementing partners
- research institutions
Named in the bill
U.S. Department of State, Centers for Disease Control and Prevention (CDC), Office of the Global AIDS Coordinator, Global Fund to Fight AIDS, Tuberculosis, and Malaria, Foreign Assistance Act of 1961, NOW (referenced in mapped stocks/sectors)
Where it stands
1 cosponsor: 1 Democrats.
- Jun 11, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jun 11, 2026 — Referred to Senate Committee on Foreign Relations · Congress.gov: “Read twice and referred to the Committee on Foreign Relations”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 9, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“U.S. commits to aggressive global TB elimination with mandatory transparency” QuorumCivic. https://share.quorumcivic.app/bill/119/s4751 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.